The interdependence between screening methods and screening libraries

Current Opinion in Chemical Biology

Volumn 11, Issue 3, 2007, Pages 244-251

  Shelat, Anang A ^a   Guy, R Kiplin ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIASTHMATIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CHEMICAL COMPOUND; CID 31300; CID 36294; CID 3911; CID 5280681; CID 5384251; CID 94741; UNCLASSIFIED DRUG;

BIOLOGY; CHEMICAL ANALYSIS; GENETIC SCREENING; PHARMACOPHORE; PHENOTYPE; REVIEW; SCREENING;

DRUG EVALUATION, PRECLINICAL; MOLECULAR STRUCTURE;

EID: 34250752914     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2007.05.003     Document Type: Review

References (51)

1. Walters W.P., and Namchuk M. Designing screens: how to make your hits a hit. Nat Rev Drug Discov 2 (2003) 259-266
2. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 1 (2002) 882-894
3. Pascual R., Borrell J.I., and Teixido J. Analysis of selection methodologies for combinatorial library design. Mol Divers 6 (2003) 121-133
4. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44 (2000) 235-249
5. Macarron R. Critical review of the role of HTS in drug discovery. Drug Discov Today 11 (2006) 277-279
6. Paolini G.V., Shapland R.H., van Hoorn W.P., Mason J.S., and Hopkins A.L. Global mapping of pharmacological space. Nat Biotechnol 24 (2006) 805-815. This study offers an interesting insight into the concepts of polypharmacology and 'druggability', the degree to which a biological target can be manipulated by an orally bioavailable molecule. Information mined from a single database linking chemical structure, structure-activity relationships and biological target reveals that approved oral small-molecule drugs primarily target a small number of human proteins. Further, the druggability of novel biological targets is reasonably predicted by identifying how compounds known to bind to the target distribute in a chemical space defined by Lipinski parameters.
7. Benjamin E.R., Pruthi F., Olanrewaju S., Ilyin V.I., Crumley G., Kutlina E., Valenzano K.J., and Woodward R.M. State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J Biomol Screen 11 (2006) 29-39
8. Desai U.A., Pallos J., Ma A.A., Stockwell B.R., Thompson L.M., Marsh J.L., and Diamond M.I. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet 15 (2006) 2114-2124
9. Rickardson L., Fryknas M., Haglund C., Lovborg H., Nygren P., Gustafsson M.G., Isaksson A., and Larsson R. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 58 (2006) 749-758
10. Oprea T.I. Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14 (2000) 251-264
11. Rishton G.M. Reactive compounds and in vitro false positives in HTS. Drug Discov Today 2 (1997) 382-384
12. Zartler E.R., and Shapiro M.J. Fragonomics: fragment-based drug discovery. Curr Opin Chem Biol 9 (2005) 366-370
13. Hann M.M., Leach A.R., and Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41 (2001) 856-864
14. Hajduk P.J. Fragment-based drug design: how big is too big?. J Med Chem 49 (2006) 6972-6976. This study presents the first comprehensive experimental (as opposed to theoretical) study of the relationship between size of molecule and binding affinity in structurally related series. The most interesting finding is that there is a very strong correlation between molecular weight and binding affinity, as predicted by Hann theory and subsequent refinements. This has strong implications, not only for fragment elaboration (providing a method to measure the efficacy of fragment optimization) but for utilization and optimization of intermediate size (lead-like) and larger (drug-like) molecules.
15. Erlanson D.A., McDowell R.S., and O'Brien T. Fragment-based drug discovery. J Med Chem 47 (2004) 3463-3482
16. Howard N., Abell C., Blakemore W., Chessari G., Congreve M., Howard S., Jhoti H., Murray C.W., Seavers L.C., and van Montfort R.L. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J Med Chem 49 (2006) 1346-1355
17. Poulsen S.A., and Bornaghi L.F. Fragment-based drug discovery of carbonic anhydrase II inhibitors by dynamic combinatorial chemistry utilizing alkene cross metathesis. Bioorg Med Chem 14 (2006) 3275-3284
18. Petros A.M., Dinges J., Augeri D.J., Baumeister S.A., Betebenner D.A., Bures M.G., Elmore S.W., Hajduk P.J., Joseph M.K., Landis S.K., et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 49 (2006) 656-663
19. Warner S.L., Bashyam S., Vankayalapati H., Bearss D.J., Han H., Von Hoff D.D., and Hurley L.H. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 5 (2006) 1764-1773
20. Newman D.J., Cragg G.M., and Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66 (2003) 1022-1037
21. Yarrow J.C., Totsukawa G., Charras G.T., and Mitchison T.J. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol 12 (2005) 385-395
22. Peterson R.T., Shaw S.Y., Peterson T.A., Milan D.J., Zhong T.P., Schreiber S.L., MacRae C.A., and Fishman M.C. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat Biotechnol 22 (2004) 595-599
23. Stegmaier K., Ross K.N., Colavito S.A., O'Malley S., Stockwell B.R., and Golub T.R. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 36 (2004) 257-263
24. Gough A.H., and Johnston P.A. Requirements, features, and performance of high content screening platforms. Methods Mol Biol 356 (2007) 41-61
25. Dunlay R.T., Czekalski W.J., and Collins M.A. Overview of informatics for high content screening. Methods Mol Biol 356 (2007) 269-280
26. Oprea T.I., and Gottfries J. Chemography: the art of navigating in chemical space. J Comb Chem 3 (2001) 157-166
27. Larsson J., Gottfries J., Bohlin L., and Backlund A. Expanding the ChemGPS chemical space with natural products. J Nat Prod 68 (2005) 985-991. The authors use the concept of chemical space to correlate structural trends among natural products with demonstrated cyclo-oxygenase (COX) 1 and COX-2 activity. The identification of several outliers suggests that some natural products might sample unique regions of property space.
28. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46 (2001) 3-26
29. Allu T.K., and Oprea T.I. Rapid evaluation of synthetic and molecular complexity for in silico chemistry. J Chem Inf Model 45 (2005) 1237-1243
30. Pearlman R.S., and Smith K.M. Metric validation and the receptor-relevant subspace concept. J Chem Inf Comput Sci 39 (1999) 28-35
31. Hall L.H., and Kier L.B. The molecular connectivity chi indexes and kappa shape indexes in structure-property modeling. In: Lipkowitz K.B., and Boyd D.B. (Eds). Reviews in Computational Chemistry (1991), VCH Publishers 367-422 [Lipkowitz KB, Boyd DB (Series Editors): Reviews in Computational Chemistry, vol 2.]
32. Root D.E., Flaherty S.P., Kelley B.P., and Stockwell B.R. Biological mechanism profiling using an annotated compound library. Chem Biol 10 (2003) 881-892
33. Sun H., Low K.E., Woo S., Noble R.L., Graham R.J., Connaughton S.S., Gee M.A., and Lee L.G. Real-time protein kinase assay. Anal Chem 77 (2005) 2043-2049
34. Young S.M., Bologa C., Prossnitz E.R., Oprea T.I., Sklar L.A., and Edwards B.S. High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J Biomol Screen 10 (2005) 374-382
35. Weisman J.L., Liou A.P., Shelat A.A., Cohen F.E., Guy R.K., and DeRisi J.L. Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des 67 (2006) 409-416
36. Do E.U., Piao L.Z., Choi G., Choi Y.B., Kang T.M., Shin J., Chang Y.J., Nam H.Y., Kim H.J., and Kim S.I. The high throughput screening of neuropeptide FF2 receptor ligands from Korean herbal plant extracts. Peptides 27 (2006) 997-1004
37. Robert F., Gao H.Q., Donia M., Merrick W.C., Hamann M.T., and Pelletier J. Chlorolissoclimides: new inhibitors of eukaryotic protein synthesis. RNA 12 (2006) 717-725
38. Swevers L., Kravariti L., Ciolfi S., Xenou-Kokoletsi M., Ragoussis N., Smagghe G., Nakagawa Y., Mazomenos B., and Iatrou K. A cell-based high-throughput screening system for detecting ecdysteroid agonists and antagonists in plant extracts and libraries of synthetic compounds. FASEB J 18 (2004) 134-136
39. Congreve M., Carr R., Murray C., and Jhoti H. A 'rule of three' for fragment-based lead discovery?. Drug Discov Today 8 (2003) 876-877
40. Schuffenhauer A., Ruedisser S., Marzinzik A.L., Jahnke W., Blommers M., Selzer P., and Jacoby E. Library design for fragment based screening. Curr Top Med Chem 5 (2005) 751-762
41. Aronov A.M., and Bemis G.W. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors. Proteins 57 (2004) 36-50
42. Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., and Jhoti H. Fragment-based lead discovery using X-ray crystallography. J Med Chem 48 (2005) 403-413
43. Martyn D.C., Jones D.C., Fairlamb A.H., and Clardy J. High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorg Med Chem Lett 17 (2007) 1280-1283
44. Holloway G.A., Baell J.B., Fairlamb A.H., Novello P.M., Parisot J.P., Richardson J., Watson K.G., and Street I.P. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorg Med Chem Lett 17 (2007) 1422-1427
45. Okun I., Malarchuk S., Dubrovskaya E., Khvat A., Tkachenko S., Kysil V., Ilyin A., Kravchenko D., Prossnitz E.R., Sklar L., et al. Screening for caspase-3 inhibitors: a new class of potent small-molecule inhibitors of caspase-3. J Biomol Screen 11 (2006) 277-285
46. Beeler A.B., Acquilano D.E., Su Q., Yan F., Roth B.L., Panek J.S., and Porco Jr. J.A. Synthesis of a library of complex macrodiolides employing cyclodimerization of hydroxy esters. J Comb Chem 7 (2005) 673-681
47. Lei X., Zaarur N., Sherman M.Y., and Porco Jr. J.A. Stereocontrolled synthesis of a complex library via elaboration of angular epoxyquinol scaffolds. J Org Chem 70 (2005) 6474-6483
48. Burke M.D., Berger E.M., and Schreiber S.L. A synthesis strategy yielding skeletally diverse small molecules combinatorially. J Am Chem Soc 126 (2004) 14095-14104
49. Goess B.C., Hannoush R.N., Chan L.K., Kirchhausen T., and Shair M.D. Synthesis of a 10,000-membered library of molecules resembling carpanone and discovery of vesicular traffic inhibitors. J Am Chem Soc 128 (2006) 5391-5403
50. Pelish H.E., Westwood N.J., Feng Y., Kirchhausen T., and Shair M.D. Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. J Am Chem Soc 123 (2001) 6740-6741
51. Tan D.S. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol 1 (2005) 74-84